Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19
Eduardo López‐Medina, Pío López, Isabel Cristina Hurtado, et al.
JAMA (2021) Vol. 325, Iss. 14, pp. 1426-1426
Open Access | Times Cited: 352

Showing 26-50 of 352 citing articles:

One Year of Coronavirus Disease 2019 (COVID-19) in Brazil: A Political and Social Overview
Matheus Negri Boschiero, Camila Vantini Capasso Palamim, Manoela Marques Ortega, et al.
Annals of Global Health (2021) Vol. 87, Iss. 1, pp. 44-44
Open Access | Times Cited: 85
Misleading clinical evidence and systematic reviews on ivermectin for COVID-19
Luis Garegnani, Eva Madrid, Nicolás Meza
BMJ evidence-based medicine (2021) Vol. 27, Iss. 3, pp. 156-158
Closed Access | Times Cited: 78
Cardiac Manifestations Of Coronavirus (COVID-19)
Indranill Basu‐Ray, Nureddin Almaddah, Adedayo Adeboye, et al.
(2021)
Closed Access | Times Cited: 77
Evaluation of Ivermectin as a Potential Treatment for Mild to Moderate COVID-19: A Double-Blind Randomized Placebo Controlled Trial in Eastern India
Ravikirti, Ranjini Roy, Chandrima Pattadar, et al.
Journal of Pharmacy & Pharmaceutical Sciences (2021) Vol. 24, pp. 343-350
Open Access | Times Cited: 70
Retracted: Meta-analysis of Randomized Trials of Ivermectin to Treat SARS-CoV-2 Infection
Andrew Hill, Anna Garratt, Jacob Levi, et al.
Open Forum Infectious Diseases (2021) Vol. 8, Iss. 11
Open Access | Times Cited: 68
Fluvoxamine for Outpatient Management of COVID-19 to Prevent Hospitalization
Todd C. Lee, Simone N. Vigod, Émilie Bortolussi‐Courval, et al.
JAMA Network Open (2022) Vol. 5, Iss. 4, pp. e226269-e226269
Open Access | Times Cited: 62
BACPI: a bi-directional attention neural network for compound–protein interaction and binding affinity prediction
Min Li, Zhangli Lu, Yifan Wu, et al.
Bioinformatics (2022) Vol. 38, Iss. 7, pp. 1995-2002
Closed Access | Times Cited: 60
SARS‐CoV‐2 and its variants of concern including Omicron: A never ending pandemic
Ranjan K. Mohapatra, Satwik Kuppili, Tarun Kumar Suvvari, et al.
Chemical Biology & Drug Design (2022) Vol. 99, Iss. 5, pp. 769-788
Open Access | Times Cited: 58
SARS-CoV-2 Antiviral Therapy
Kaiming Tao, Philip L. Tzou, Janin Nouhin, et al.
Clinical Microbiology Reviews (2021) Vol. 34, Iss. 4
Open Access | Times Cited: 57
Hierarchical graph representation learning for the prediction of drug-target binding affinity
Zhaoyang Chu, Feng Huang, Haitao Fu, et al.
Information Sciences (2022) Vol. 613, pp. 507-523
Open Access | Times Cited: 43
Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity
Ashley Jia Wen Yip, Zheng Yao Low, Vincent Chow, et al.
Viruses (2022) Vol. 14, Iss. 6, pp. 1345-1345
Open Access | Times Cited: 38
The scenario of self-medication practices during the covid-19 pandemic; a systematic review
Abhigan Babu Shrestha, Manjil Aryal, Junu Rana Magar, et al.
Annals of Medicine and Surgery (2022) Vol. 82
Open Access | Times Cited: 38
Effectiveness of Drug Repurposing and Natural Products Against SARS-CoV-2: A Comprehensive Review
Paula Andrea Cuartas Velásquez, Juan C. Hernández, Elkin Galeano, et al.
Clinical Pharmacology Advances and Applications (2024) Vol. Volume 16, pp. 1-25
Open Access | Times Cited: 10
N-Acetylcysteine as Adjuvant Therapy for COVID-19 – A Perspective on the Current State of the Evidence
Kon Ken Wong, Shaun Wen Huey Lee, Kok Pim Kua
Journal of Inflammation Research (2021) Vol. Volume 14, pp. 2993-3013
Open Access | Times Cited: 52
Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): A single-centre randomized, placebo-controlled trial
Anant Mohan, Pawan Tiwari, Tejas Menon Suri, et al.
Journal of Infection and Chemotherapy (2021) Vol. 27, Iss. 12, pp. 1743-1749
Open Access | Times Cited: 51
Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients
Morteza Shakhsi Niaee, Peyman Namdar, Abbas Allami, et al.
Asian Pacific Journal of Tropical Medicine (2021) Vol. 14, Iss. 6, pp. 266-273
Open Access | Times Cited: 48
Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19
Azita H. Talasaz, Parham Sadeghipour, Maryam Aghakouchakzadeh, et al.
Journal of the American College of Cardiology (2021) Vol. 78, Iss. 16, pp. 1635-1654
Open Access | Times Cited: 45
Ivermectin and outcomes from Covid‐19 pneumonia: A systematic review and meta‐analysis of randomized clinical trial studies
Timotius Ivan Hariyanto, Devina Adella Halim, Jane Rosalind, et al.
Reviews in Medical Virology (2021) Vol. 32, Iss. 2
Open Access | Times Cited: 44
Repositioning Ivermectin for Covid-19 treatment: Molecular mechanisms of action against SARS-CoV-2 replication
Zheng Yao Low, Ashley Jia Wen Yip, Sunil K. Lal
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2021) Vol. 1868, Iss. 2, pp. 166294-166294
Open Access | Times Cited: 41
Systematic review and meta-analysis of ivermectin for treatment of COVID-19: evidence beyond the hype
Milena Soriano Marcolino, Karina Cardoso Meira, Nathália Sernizon Guimarães, et al.
BMC Infectious Diseases (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 30
COVID-19 and the promise of small molecule therapeutics: Are there lessons to be learnt?
Wei Shen Ho, Ruirui Zhang, Yeong Lan Tan, et al.
Pharmacological Research (2022) Vol. 179, pp. 106201-106201
Open Access | Times Cited: 29
Drug repositioning in the COVID-19 pandemic: fundamentals, synthetic routes, and overview of clinical studies
Elisa Souza Vaz, Sandra V. Vassiliades, Jeanine Giarolla, et al.
European Journal of Clinical Pharmacology (2023) Vol. 79, Iss. 6, pp. 723-751
Open Access | Times Cited: 16
Inhalable spray-dried dry powders combining ivermectin and niclosamide to inhibit SARS-CoV-2 infection in vitro
Catherine K. Su, Tushar Saha, Shubhra Sinha, et al.
International Journal of Pharmaceutics (2025), pp. 125302-125302
Closed Access
Repurposing of FDA‐approved drugs against active site and potential allosteric drug‐binding sites of COVID‐19 main protease
Merve Yuce, Erdem Cicek, Tuğçe İnan, et al.
Proteins Structure Function and Bioinformatics (2021) Vol. 89, Iss. 11, pp. 1425-1441
Open Access | Times Cited: 39
Coronavirus Disease (COVID-19) Control between Drug Repurposing and Vaccination: A Comprehensive Overview
Ahmed A. Al‐Karmalawy, Raya Soltane, Ayman Abo Elmaaty, et al.
Vaccines (2021) Vol. 9, Iss. 11, pp. 1317-1317
Open Access | Times Cited: 39

Scroll to top